vs
Mativ Holdings, Inc.（MATV）与PHIBRO ANIMAL HEALTH CORP（PAHC）财务数据对比。点击上方公司名可切换其他公司
Mativ Holdings, Inc.的季度营收约是PHIBRO ANIMAL HEALTH CORP的1.2倍（$463.1M vs $373.9M），Mativ Holdings, Inc.净利率更高（21.8% vs 7.3%，领先14.4%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 1.0%），PHIBRO ANIMAL HEALTH CORP自由现金流更多（$8.3M vs $8.0M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs -3.8%）
Mativ Holdings是一家全球特种材料制造商，主要生产高性能先进聚合物、无纺布、过滤解决方案及功能性涂层材料，服务医疗、工业、消费品、航空航天、能源等领域，业务遍及北美、欧洲及亚太地区。
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
MATV vs PAHC — 直观对比
营收规模更大
MATV
是对方的1.2倍
$373.9M
营收增速更快
PAHC
高出19.9%
1.0%
净利率更高
MATV
高出14.4%
7.3%
自由现金流更多
PAHC
多$255.0K
$8.0M
两年增速更快
PAHC
近两年复合增速
-3.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $463.1M | $373.9M |
| 净利润 | $100.8M | $27.5M |
| 毛利率 | 18.8% | 35.5% |
| 营业利润率 | 2.2% | 13.5% |
| 净利率 | 21.8% | 7.3% |
| 营收同比 | 1.0% | 20.9% |
| 净利润同比 | 6620.0% | 762.1% |
| 每股收益（稀释后） | $1.87 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MATVPAHC
| Q4 25 | $463.1M | $373.9M | ||
| Q3 25 | $513.7M | $363.9M | ||
| Q2 25 | $525.4M | $378.7M | ||
| Q1 25 | $484.8M | $347.8M | ||
| Q4 24 | $458.6M | $309.3M | ||
| Q3 24 | $498.5M | $260.4M | ||
| Q2 24 | $523.8M | $273.2M | ||
| Q1 24 | $500.2M | $263.2M |
净利润MATVPAHC
| Q4 25 | $100.8M | $27.5M | ||
| Q3 25 | $-3.2M | $26.5M | ||
| Q2 25 | $-9.5M | $17.2M | ||
| Q1 25 | $-425.5M | $20.9M | ||
| Q4 24 | $1.5M | $3.2M | ||
| Q3 24 | $-20.8M | $7.0M | ||
| Q2 24 | $-1.4M | $752.0K | ||
| Q1 24 | $-28.0M | $8.4M |
毛利率MATVPAHC
| Q4 25 | 18.8% | 35.5% | ||
| Q3 25 | 19.3% | 32.9% | ||
| Q2 25 | 19.7% | 29.0% | ||
| Q1 25 | 15.0% | 30.1% | ||
| Q4 24 | 16.9% | 32.9% | ||
| Q3 24 | 18.8% | 32.1% | ||
| Q2 24 | 20.8% | 31.9% | ||
| Q1 24 | 16.8% | 30.2% |
营业利润率MATVPAHC
| Q4 25 | 2.2% | 13.5% | ||
| Q3 25 | 3.1% | 14.1% | ||
| Q2 25 | 3.8% | 8.9% | ||
| Q1 25 | -88.8% | 9.6% | ||
| Q4 24 | 0.6% | 8.3% | ||
| Q3 24 | 1.4% | 6.8% | ||
| Q2 24 | 2.0% | 6.7% | ||
| Q1 24 | -2.8% | 7.6% |
净利率MATVPAHC
| Q4 25 | 21.8% | 7.3% | ||
| Q3 25 | -0.6% | 7.3% | ||
| Q2 25 | -1.8% | 4.5% | ||
| Q1 25 | -87.8% | 6.0% | ||
| Q4 24 | 0.3% | 1.0% | ||
| Q3 24 | -4.2% | 2.7% | ||
| Q2 24 | -0.3% | 0.3% | ||
| Q1 24 | -5.6% | 3.2% |
每股收益（稀释后）MATVPAHC
| Q4 25 | $1.87 | $0.67 | ||
| Q3 25 | $-0.06 | $0.65 | ||
| Q2 25 | $-0.18 | $0.43 | ||
| Q1 25 | $-7.82 | $0.51 | ||
| Q4 24 | $0.03 | $0.08 | ||
| Q3 24 | $-0.38 | $0.17 | ||
| Q2 24 | $-0.03 | $0.02 | ||
| Q1 24 | $-0.52 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $84.2M | $74.5M |
| 总债务越低越好 | $1.0B | $624.2M |
| 股东权益账面价值 | $498.7M | $332.4M |
| 总资产 | $2.1B | $1.4B |
| 负债/权益比越低杠杆越低 | 2.07× | 1.88× |
8季度趋势，按日历期对齐
现金及短期投资MATVPAHC
| Q4 25 | $84.2M | $74.5M | ||
| Q3 25 | $97.1M | $85.3M | ||
| Q2 25 | $95.6M | $77.0M | ||
| Q1 25 | $84.0M | $70.4M | ||
| Q4 24 | $94.3M | $67.1M | ||
| Q3 24 | $162.2M | $89.8M | ||
| Q2 24 | $133.4M | $114.6M | ||
| Q1 24 | $128.9M | $98.7M |
总债务MATVPAHC
| Q4 25 | $1.0B | $624.2M | ||
| Q3 25 | $1.0B | $628.0M | ||
| Q2 25 | $1.1B | $631.7M | ||
| Q1 25 | $1.1B | $635.4M | ||
| Q4 24 | $1.1B | $639.1M | ||
| Q3 24 | $1.2B | $295.2M | ||
| Q2 24 | $1.2B | $312.1M | ||
| Q1 24 | $1.2B | — |
股东权益MATVPAHC
| Q4 25 | $498.7M | $332.4M | ||
| Q3 25 | $397.4M | $311.7M | ||
| Q2 25 | $416.6M | $285.7M | ||
| Q1 25 | $428.2M | $266.0M | ||
| Q4 24 | $858.5M | $246.8M | ||
| Q3 24 | $882.3M | $258.5M | ||
| Q2 24 | $898.0M | $256.6M | ||
| Q1 24 | $906.9M | $270.1M |
总资产MATVPAHC
| Q4 25 | $2.1B | $1.4B | ||
| Q3 25 | $2.0B | $1.4B | ||
| Q2 25 | $2.1B | $1.4B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.4B | $1.3B | ||
| Q3 24 | $2.6B | $966.3M | ||
| Q2 24 | $2.6B | $982.2M | ||
| Q1 24 | $2.7B | $979.0M |
负债/权益比MATVPAHC
| Q4 25 | 2.07× | 1.88× | ||
| Q3 25 | 2.63× | 2.01× | ||
| Q2 25 | 2.66× | 2.21× | ||
| Q1 25 | 2.67× | 2.39× | ||
| Q4 24 | 1.30× | 2.59× | ||
| Q3 24 | 1.32× | 1.14× | ||
| Q2 24 | 1.29× | 1.22× | ||
| Q1 24 | 1.30× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.3M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $8.0M | $8.3M |
| 自由现金流率自由现金流/营收 | 1.7% | 2.2% |
| 资本支出强度资本支出/营收 | 2.4% | 3.0% |
| 现金转化率经营现金流/净利润 | 0.19× | 0.70× |
| 过去12个月自由现金流最近4个季度 | $93.8M | $47.3M |
8季度趋势，按日历期对齐
经营现金流MATVPAHC
| Q4 25 | $19.3M | $19.4M | ||
| Q3 25 | $72.8M | $9.3M | ||
| Q2 25 | $57.6M | $21.3M | ||
| Q1 25 | $-15.9M | $43.2M | ||
| Q4 24 | $24.1M | $3.1M | ||
| Q3 24 | $37.6M | $12.6M | ||
| Q2 24 | $46.1M | $28.4M | ||
| Q1 24 | $-13.0M | $11.4M |
自由现金流MATVPAHC
| Q4 25 | $8.0M | $8.3M | ||
| Q3 25 | $66.7M | $-4.5M | ||
| Q2 25 | $48.9M | $8.1M | ||
| Q1 25 | $-29.8M | $35.4M | ||
| Q4 24 | $2.0M | $-4.7M | ||
| Q3 24 | $25.5M | $3.0M | ||
| Q2 24 | $37.4M | $15.4M | ||
| Q1 24 | $-25.1M | $1.7M |
自由现金流率MATVPAHC
| Q4 25 | 1.7% | 2.2% | ||
| Q3 25 | 13.0% | -1.2% | ||
| Q2 25 | 9.3% | 2.1% | ||
| Q1 25 | -6.1% | 10.2% | ||
| Q4 24 | 0.4% | -1.5% | ||
| Q3 24 | 5.1% | 1.2% | ||
| Q2 24 | 7.1% | 5.6% | ||
| Q1 24 | -5.0% | 0.6% |
资本支出强度MATVPAHC
| Q4 25 | 2.4% | 3.0% | ||
| Q3 25 | 1.2% | 3.8% | ||
| Q2 25 | 1.7% | 3.5% | ||
| Q1 25 | 2.9% | 2.2% | ||
| Q4 24 | 4.8% | 2.5% | ||
| Q3 24 | 2.4% | 3.7% | ||
| Q2 24 | 1.7% | 4.8% | ||
| Q1 24 | 2.4% | 3.7% |
现金转化率MATVPAHC
| Q4 25 | 0.19× | 0.70× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 2.07× | ||
| Q4 24 | 16.07× | 0.97× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 37.80× | ||
| Q1 24 | — | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
